Drugs with anticholinergic action are widely prescribed in the elderly population due to their potential clinical benefits. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
With the unprecedented aging of the world's population, the number of elderly patients with depression is expected to increase. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Average caregiver burden on the ZBI was 36.1 (SD = 14.6; range = 12-58). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a terminal illness that leads to progressive cognitive and functional decline. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Elderly people are more likely than younger patients to develop cognitive impairment as a result of taking medications. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Anticholinergic toxicity is a common problem in the elderly. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Medications with anticholinergic activity negatively affect the cognitive performance of older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The acquired immunodeficiency syndrome (AIDS) and its related conditions are a public health problem of unprecedented proportions due to the debilitating and fatal nature of the disease, the sociocultural implications related to contagion, and its initial appearance in certain socially stigmatized groups. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
40/100
ACS occurs in one fourth of stroke patients older than 40 years. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The advent of highly active antiretroviral therapy has prolonged the life expectancy of HIV patients and decreased the number of adults who progress to AIDS and HIV-associated dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Peri-operative neurocognitive disorders are the most common complication experienced by older individuals undergoing anaesthesia and surgery. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As populations age, heart failure (HF) is becoming increasingly common, and in addition to a high burden of morbidity and mortality, HF has an enormous financial impact. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Most psychiatric disorders are associated with increased oxidative stress. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In patients with end-stage renal disease, nervous system dysfunction remains a major cause of disability. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Depression is a frequent cause of morbidity in surgery patients suffering from a wide range of conditions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Biomarkers specific to AD pathology (p-tau217, GFAP) rather than peripheral inflammation had robust prognostic value in established AD. 5 key findings →
Participants: 333 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
39/100
With the growing care needs for the older population at the end of their lives, there has been a substantial increase in attention to the management of the patient with dementia in hospice and palliative care services. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The assessment and treatment of pain in persons with cognitive impairments pose unique challenges. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The burden of perioperative organ injury in China is significant even at a national level. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
376 323 elective geriatric THA patient samples from the NIS database were included, with an overall dementia prevalence of 2.05%. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Postoperative cognitive dysfunction (POCD) is an objectively measured decline in cognition postoperatively compared with preoperative function. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
In the sample studied, music therapy improved some cognitive, psychological, and behavioural alterations in patients with Alzheimer disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This review highlights the need to integrate trauma-informed practices into hospice and palliative care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
38/100
Anosmia, stroke, paralysis, cranial nerve deficits, encephalopathy, delirium, meningitis, and seizures are some of the neurological complications in patients with coronavirus disease-19 (COVID-19) which is caused by acute respiratory syndrome coronavirus 2 (SARS-Cov2). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The blood-brain barrier (BBB) plays a key role in maintaining the specialized microenvironment of the central nervous system (CNS), and enabling communication with the systemic compartment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →